If you can spare a few minutes, please help us improve our website by completing this survey.
While the journey from bench to bedside can be long and arduous, a well-built bridge makes the path significantly shorter. Life scientists and engineers from MIT’s Koch Institute for Integrative Cancer Research and physician scientists from Dana-Farber/Harvard Cancer Center have teamed up through the collaborative, award-winning Bridge Project to develop and expedite the use of innovative technologies for clinical application and treatment. This event featured two projects that are fighting back against recurring cancers, using microfluidic technology and vaccines, respectively, and explored some of the ways in which our Bridge Project researchers are upending resistance and relapse from both sides of the river.
Development of an ALK Vaccine for Lung Cancer Treatment
Presented by Mark Awad (Dana-Farber Cancer Institute), Roberto Chiarle (Boston Children's Hospital), Darrell Irvine (Koch Institute at MIT)
Targeting Minimal Residual Disease in Acute Leukemias
Presented by Scott Manalis (Koch Institute at MIT) and David Weinstock (Dana-Farber Cancer Institute)
With additional remarks by Bridge Project Founding Donor Arthur Gelb (ScD ’61)